Related Experiment Videos
Rationalized assessment of prolonged jaundice is safe and cost-effective
1Neonatal Unit, Southern General Hospital, Glasgow, Scotland, UK. martina.rodie@nhs.net
Insights
A new guideline for prolonged jaundice (PJ) in newborns significantly reduced unnecessary appointments and tests. This approach is cost-effective but doesn't identify all cases of liver disease, suggesting population-based screening may be better.
Area of Science:
- Neonatal Medicine
- Pediatric Gastroenterology
- Clinical Auditing
Background:
- Prolonged jaundice (PJ) in healthy term neonates is common but can indicate serious liver disease.
- Current assessment methods for PJ show significant variation.
- A balanced approach is needed to avoid over-investigation while detecting pathology early.
Purpose of the Study:
- To audit the management of prolonged jaundice in neonatal units.
- To evaluate the impact of a rationalized investigation algorithm based on BSPGHAN guidelines.
- To assess the effectiveness and cost-efficiency of the new algorithm.
Main Methods:
- Prospective audit of PJ management over two years in two Level 3 neonatal units.
- Comparison of practice before and after implementing a standardized algorithm (clinical exam, stool inspection, split bilirubin).
- Inclusion of 197 neonates referred with PJ (105 pre-algorithm, 92 post-algorithm).
Main Results:
- No underlying liver pathology was identified in the studied neonates with PJ.
- The rationalized algorithm led to a significant reduction in return appointments (28 vs. 7) and repeat investigations (37 vs. 7).
- Cost savings of £1575-£2625 annually in laboratory costs were observed.
Conclusions:
- A rationalized approach to assessing prolonged jaundice is effective, reduces workload, and is cost-effective.
- Selective screening for PJ has limitations, as evidenced by three infants with biliary atresia diagnosed late.
- Population-based screening methods warrant further consideration for identifying cholestatic liver disease.
Abstract:
Prolonged jaundice (PJ) in healthy term neonates is common and frequently benign. It can, however, be the earliest manifestation of underlying liver disease. Its management requires a balanced approach, avoiding over-investigation of well babies while ensuring the early identification of those with pathology. Currently marked heterogeneity exists in the assessment of PJ. Over a two-year period we prospectively audited the management of PJ in two Level 3 neonatal units prior to and after the introduction of a rationalized investigation algorithm in keeping with the recently published British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) guidelines (i.e. clinical examination and stool inspection combined with measurement of split bilirubin). In this study we reviewed initial practice and then evaluated the impact of our change in practice. A total of 197 babies, 1.5% of live births, were referred with PJ. Of these, 105 babies were included in the first part of the study and 92 babies were included in the second part. No pathology relating to PJ, such as infection, hepatitis or liver disease, was identified. Following the introduction of our rationalized algorithm, we demonstrated a statistically significant reduction in the number of return appointments (28 versus 7; P < 0.0009) and repeat investigations (37 versus 7; P < 0.0001). This represented a saving of £1575-2625 per year in laboratory costs alone. Contemporaneously, three infants presented with biliary atresia, none of whom were identified by PJ screening and all of whom were over seven weeks old at diagnosis. A rationalized approach to the assessment of PJ reduces workload and is cost-effective; however, the limitations of selective screening, irrespective of how streamlined it is, remain--if babies are not identified and referred, they cannot be screened. Population-based methodologies offer an alternative approach to the identification of cholestatic liver disease and are worthy of further consideration.
Related Concept Videos
Jaundice
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Acute Kidney Injury IV: Diagnostic Studies and Prevention